Biomarkers in Inflammatory Bowel Disease-Associated Spondyloarthritis: State of the Art and Unmet Needs.

Devis Benfaremo,Michele Maria Luchetti,Armando Gabrielli

doi:10.1155/2019/8630871

Devis Benfaremo, Michele Maria Luchetti + Show 1 more

Open Access

https://doi.org/10.1155/2019/8630871

Copy DOI

Abstract

Inflammatory bowel disease-associated spondyloarthritis is a systemic disease characterized by the chronic inflammation of both the gastrointestinal tract and the musculoskeletal system. Since inflammatory bowel disease-associated spondyloarthritis has been associated with a significant diagnostic delay, which may lead to poor quality of life and progression of joint damage, efforts to discover new reliable and noninvasive diagnostic biomarkers have been made. We reviewed the state of the art of biomarker research in inflammatory bowel disease-associated spondyloarthritis, showing that to date it has been largely unsatisfactory. Only a few of the biomarkers that have been investigated are likely to enter the clinical practice upon further validation in independent cohorts. The research of new and innovative biomarkers for inflammatory bowel disease-associated spondyloarthritis is warranted.

Highlights

Inflammatory bowel disease-associated spondyloarthritis (SpA/inflammatory bowel diseases (IBD)) is a systemic disease characterized by the chronic inflammation of both the gastrointestinal tract and the musculoskeletal system [1]
179 patients: 52 with ankylosing spondylitis (AS), 50 with ulcerative colitis (UC), 51 with perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) associated with UC in AS patients
179 patients: 52 with AS, 50 with UC, 51 with anti-Saccharomyces cerevisiae (ASCA) found in 40% of SpA/Crohn’s disease (CD) vs. 30% of AS and 90%

Summary

Introduction

Inflammatory bowel disease-associated spondyloarthritis (SpA/IBD) is a systemic disease characterized by the chronic inflammation of both the gastrointestinal tract and the musculoskeletal system [1]. Ustekinumab, the first IL-12/23 inhibitor, is approved for the treatment of CD but failed to improve symptoms and signs of axial SpA [11] Taken together, these differences suggest that, despite the several features that SpA and IBD have in common, the coexistence of joint and gut inflammations is unique. These differences suggest that, despite the several features that SpA and IBD have in common, the coexistence of joint and gut inflammations is unique This is further suggested by the proportion of human leukocyte antigen- (HLA-) B27-positive patients in the axial SpA/IBD group, far lower than AS and SpA in general [3, 12, 13]. Referral strategies such as the use of screening questionnaires [15] and the identification of simple biomarkers are warranted

What Are Biomarkers?

Findings

59 IBD patients with or without peripheral SpA

Conclusions